SNYR — Synergy CHC Corp.

Summary of Synergy CHC Corporation (SNYR) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Revenue: $6.07 million, down 41% from $10.27 million in Q4 2024. Excluding a $2.9 million reversal from a terminated licensing agreement, revenue decreased by 12.7%.
• Gross Margin: 36.6%, significantly down from 63.3% year-over-year, primarily due to the licensing agreement termination and a $1.04 million inventory write-off. Normalized gross margin would have been 68.8%.
• Operating Expenses: Increased to $15.53 million from $5.14 million in Q4 2024, largely due to a $6.6 million bad debt allowance and a $0.9 million prepaid media credit write-off.
• Net Loss: $14.82 million ($1.35 per diluted share), compared to a net income of $105,700 in Q4 2024. Adjusted for one-time items, the loss would be $3.35 million.
• Full Year 2025 Revenue: $30.38 million, down from $34.83 million in 2024. Adjusted revenue, excluding the licensing reversal, would be $33.28 million.
• Net Loss for 2025: $12.3 million ($1.27 per diluted share), compared to a net income of $2.1 million in 2024.

2. Strategic Updates and Business Highlights

• International Expansion: The company established a wholly-owned subsidiary in Mexico and initiated product shipments to Costco Mexico, generating over $600,000 in gross revenue in Q1 2026.
• Product Distribution: Significant distribution agreements were made with various retailers for ready-to-drink (RTD) products, with expectations of substantial growth in 2026.
• Advertising Strategy: Plans to resume TV advertising in 2026, which historically has driven a 15% lift in same-store sales.

3. Forward Guidance and Outlook

• 2026 Expectations: The company anticipates 2026 to be a foundational growth year for its beverage division, with a focus on executing previously laid initiatives, including TV advertising and expanding the retail network in Mexico.
• Gross Margin Outlook: Management expects gross margins to stabilize or improve, excluding one-time impacts from 2025.

4. Bad News, Challenges, or Points of Concern

• Termination of Licensing Agreement: The loss of $2.5 million in expected revenue due to the termination of the international license agreement for the UAE and Turkey due to regional instability.
• Increased Operating Expenses: Significant one-time costs have negatively impacted financial results, raising concerns about ongoing operational efficiency.
• Declining Product Lines: The Flat Tummy product line continues to decline, affected by competition from GLP-1 medications, prompting a strategic review.

5. Notable Q&A Insights

• RTD Inventory Issues: Delays in inventory buildup affected Q4 revenue; the majority of RTD inventory was received in December 2025.
• Core Supplement Performance: The core supplement business remains strong, but the need for renewed advertising is critical to compete effectively.
• Future International Expansion: No immediate plans for further international subsidiaries beyond Mexico, focusing instead on executing existing initiatives.

Overall, while Synergy CHC Corporation faced significant challenges in Q4 2025, including revenue declines and increased losses, the company is positioning itself for potential growth in 2026 through strategic initiatives and market expansion.